Vacino Biotech
Biotechnology company founded in 2020 focused on peptide-based broad-spectrum vaccines, chemically modified single-stranded RNA therapeutics, and a peptide-targeting brain delivery platform. The organization develops epitope peptide vaccine design, oligonucleotide modification chemistries, receptor-targeting peptides for blood-brain-barrier (BBB) transcytosis, and associated preclinical development toward IND filing and GMP production.
Industries
Nr. of Employees
small (1-50)
Vacino Biotech
4F, No. 99, Lane 130, Sec. 1, Academia Rd., Nangang District, Taipei City, Taiwan (National Biotechnology Research Park, Building C, Room 418)
Products
Vacino-CO (oral HLA-restricted peptide COVID-19 vaccine)
Oral peptide vaccine based on short HLA-restricted epitopes derived from conserved regions of SARS-CoV-2 spike protein; designed to induce T cell and B cell immunity including mucosal IgA and to be protease-resistant for oral dosing.
Vacino-ADmir (microRNA-based therapeutic for Alzheimer's disease)
Chemically synthesized microRNA therapeutic designed to upregulate neuronal PD-L1 expression to modulate microglia activation; includes targeting peptide, lysosome-sensitive release sequence, and stabilizing polymer for brain targeting.
VBT brain delivery platform (transferrin-receptor targeting peptides)
Peptide-based targeting platform that binds transferrin receptor to enable receptor-mediated transcytosis across the BBB, applicable to small molecules, biologics, short RNA, LNPs and viral vectors.
V-HERbrain (brain-shuttle antibody)
Therapeutic antibody chemically modified with a VBT targeting peptide to enable simultaneous treatment of peripheral and intracranial tumors via enhanced brain penetration.
V-GOBrain (VBT-tagged lipid nanoparticles)
LNP formulations embedded with VBT targeting peptides to facilitate brain delivery following intravenous or oral administration; designed to carry nucleic acid cargos (DNA/mRNA/siRNA/miRNA).
Vacino-CO (oral HLA-restricted peptide COVID-19 vaccine)
Oral peptide vaccine based on short HLA-restricted epitopes derived from conserved regions of SARS-CoV-2 spike protein; designed to induce T cell and B cell immunity including mucosal IgA and to be protease-resistant for oral dosing.
Vacino-ADmir (microRNA-based therapeutic for Alzheimer's disease)
Chemically synthesized microRNA therapeutic designed to upregulate neuronal PD-L1 expression to modulate microglia activation; includes targeting peptide, lysosome-sensitive release sequence, and stabilizing polymer for brain targeting.
VBT brain delivery platform (transferrin-receptor targeting peptides)
Peptide-based targeting platform that binds transferrin receptor to enable receptor-mediated transcytosis across the BBB, applicable to small molecules, biologics, short RNA, LNPs and viral vectors.
V-HERbrain (brain-shuttle antibody)
Therapeutic antibody chemically modified with a VBT targeting peptide to enable simultaneous treatment of peripheral and intracranial tumors via enhanced brain penetration.
V-GOBrain (VBT-tagged lipid nanoparticles)
LNP formulations embedded with VBT targeting peptides to facilitate brain delivery following intravenous or oral administration; designed to carry nucleic acid cargos (DNA/mRNA/siRNA/miRNA).
Services
Partnership-based research and co-development for vaccine and nucleic acid therapeutic programs, including joint preclinical studies and technology transfer.
Partnership-based research and co-development for vaccine and nucleic acid therapeutic programs, including joint preclinical studies and technology transfer.
Expertise Areas
- Peptide epitope vaccine development
- Nucleic acid therapeutics (miRNA/siRNA) design and modification
- Brain drug delivery and blood-brain-barrier transcytosis
- Lipid nanoparticle formulation and modification
Key Technologies
- Epitope peptide vaccine design
- Single-stranded RNA chemical modification
- Transferrin receptor-mediated transcytosis targeting
- Lipid nanoparticle (LNP) modification
News & Updates
Preclinical publication describing a nonadjuvanted HLA-restricted peptide vaccine that induced T and B cell immunity against SARS-CoV-2 spike protein; associated peptide epitopes were deposited in an epitope database.
National patent approval for a short targeting peptide brain-delivery technology that enables transcytosis across the blood-brain barrier and has been applied to antibodies and lipid nanoparticles.
National patent approval for a microRNA-based therapeutic approach designed to upregulate PD-L1 in neurons to reduce neuroinflammation in Alzheimer’s disease.
National patent approval for an oral peptide-based COVID-19 vaccine designed to induce neutralizing antibodies, T cell responses and mucosal IgA.
Candidate broad-spectrum COVID-19 peptide vaccine listed in the WHO COVID-19 vaccine tracker and landscape.
Shortlisted for a vaccine technology platform award at an international vaccine conference (World Vaccine Congress).
Preclinical publication describing a nonadjuvanted HLA-restricted peptide vaccine that induced T and B cell immunity against SARS-CoV-2 spike protein; associated peptide epitopes were deposited in an epitope database.
National patent approval for a short targeting peptide brain-delivery technology that enables transcytosis across the blood-brain barrier and has been applied to antibodies and lipid nanoparticles.
National patent approval for a microRNA-based therapeutic approach designed to upregulate PD-L1 in neurons to reduce neuroinflammation in Alzheimer’s disease.
National patent approval for an oral peptide-based COVID-19 vaccine designed to induce neutralizing antibodies, T cell responses and mucosal IgA.
Candidate broad-spectrum COVID-19 peptide vaccine listed in the WHO COVID-19 vaccine tracker and landscape.
Shortlisted for a vaccine technology platform award at an international vaccine conference (World Vaccine Congress).